Treatment for the chronic phase of CML typically includes imatinib (Gleevec).
For patients who cannot tolerate imatinib, other options include a new vaccine. Investigators at Memorial Sloan-Kettering and other cancer centers are also looking into ways to extend the effectiveness of imatinib by combining it with other agents known to be active against CML, including interferon.
